Regulatory action on rosiglitazone by the U.S. Food and Drug Administration

N Engl J Med. 2010 Oct 14;363(16):1489-91. doi: 10.1056/NEJMp1010788. Epub 2010 Sep 23.

Authors

Janet Woodcock¹, Joshua M Sharfstein, Margaret Hamburg

Affiliation

¹ Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, Silver Spring, MD, USA.

PMID: 20942663
DOI: 10.1056/NEJMp1010788

No abstract available

MeSH terms

Cardiovascular Diseases / chemically induced
Cardiovascular Diseases / mortality
Diabetes Mellitus, Type 2 / drug therapy*
Drug and Narcotic Control*
Humans
Myocardial Infarction / chemically induced
Rosiglitazone
Thiazolidinediones / adverse effects*
Thiazolidinediones / therapeutic use
United States
United States Food and Drug Administration*

Substances

Thiazolidinediones
Rosiglitazone